S&P Futures
4,016.25 +14.75 (+0.37%) Dow Futures
32,680.00 +92.00 (+0.28%) Nasdaq Futures
12,783.00 +50.50 (+0.40%) Russell 2000 Futures
1,773.50 +8.70 (+0.49%) Crude Oil
73.74 +0.54 (+0.74%) Gold
1,969.70 -3.80 (-0.19%)
Precipio, Inc. (PRPO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6500 |
| Open | 0.6400 |
| Bid | 0.6074 x 1200 |
| Ask | 0.7000 x 900 |
| Day's Range | 0.6240 - 0.6502 |
| 52 Week Range | 0.4700 - 1.7700 |
| Volume | |
| Avg. Volume | 88,421 |
| Market Cap | 14.24M |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8480 |
| Earnings Date | Apr 03, 2023 - Apr 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- GlobeNewswire
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ETNEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Pre
- GlobeNewswire
Precipio Ships First IV-Cell® Order to Major US Healthcare System
Products Division revenues begin to diversify beyond HemeScreen®NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system. The healthcare system (unnamed for competitive reasons) has successfully completed the validation of the media and will begin the gradual incorporation into clinical use. About IV-Cel
- GlobeNewswire
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growthNEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read "revenues in Q2-2023 are now estimated to be ~50% greater than Q1-2023" rather than "~50% greater than Q1-2022". The corrected release follows: Specialty cancer diagnostics company
